Skip to main content
SpringerLink
Log in
Book cover

Cardiovascular Pharmacogenetics pp 203–222Cite as

Genetic Determinants of Susceptibility, Prognosis and Treatment in Heart Failure

  • Chapter

  • 187 Accesses

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 160))

Abstract

Heart failure is a major burden on public health resources and the prevalence of the condition is rising as the population ages and with the increasing success of salvage strategies for myocardial infarction. The emphasis in management has changed over the last 20 years from the use of predominantly inotropic agents to drugs that regulate neurohumoral activity. This has reaped rewards in terms of improving reducing mortality but much remains to be done. Now, in common with the approach taken to other cardiovascular diseases, there is considerable interest in the use of genetic information to refine and personalize the treatment of heart failure, in the expectation that this will bring about further benefits to the patient and a more rational use of resources. The genetic information that may be of use in this respect is very wide ranging, encompassing factors that predispose to the disease (through atheroma, hypertension, resistance to oxidative damage, etc.), and genetic traits that influence prognosis, the ability to metabolize drugs and drug targets. This review will focus on studies in humans that have investigated the relationship between genotypes in candidate genes and susceptibility to heart failure, prognosis and response to treatment. In general these studies have been conducted on relatively small patient groups and as such have not yielded conclusive results which have changed clinical practice. Nonetheless, the studies provide encouragement and a basis for further investigations in larger, well-characterized populations.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andersson B, Blange I, Sylven C (1999) Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail. 1: 363–369

    Article  PubMed  CAS  Google Scholar 

  • Andersson B, Sylven C (1996) The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 28: 162–167

    Article  PubMed  CAS  Google Scholar 

  • Baruch L, Anand I, Cohen IS et al (1999) Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial ( V-HeFT) Study Group. Circulation. 99: 2658–2664

    Google Scholar 

  • Benetos A, Gautier S, Ricard S et al (1996) Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation. 94: 698–703

    Article  PubMed  CAS  Google Scholar 

  • Borjesson M, Magnusson Y, Hjalmarson A et al (2000) A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 21: 1853–1858

    Article  PubMed  CAS  Google Scholar 

  • Cambien F, Poirier O, Lecerf L et al (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641–644

    Article  PubMed  CAS  Google Scholar 

  • Charron P, Komajda M (2001) Are we ready for pharmacogenomics in heart failure? Eur J Pharm 417: 1–9.

    Article  CAS  Google Scholar 

  • Charron P, Tesson F, Poirier O et al (1999) Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 20: 1587–1591

    Google Scholar 

  • CIBIS-II Investigators and Committee (1999) The cardiac insufficiency bisoprolol study II. Lancet 353: 9–13

    Google Scholar 

  • Cicoira M, Zanolla L, Rossi A et al (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme ( ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardioll. 37: 1808–1812

    Google Scholar 

  • Cockcroft JR, Gazis AG, Cross DJ et al (2000) Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36: 371–375

    Article  PubMed  CAS  Google Scholar 

  • Cusi D, Barlassina C, Azzani T et al (1997) Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349 (9062): 353–1357

    Article  Google Scholar 

  • Davies E, Holloway CD, Ingram MC et al (1999) Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene. Hypertension 33: 703–707

    Article  PubMed  CAS  Google Scholar 

  • De Groote P, Lamblin N et al (2001) Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circ 102 Suppl. IL: 661.

    Google Scholar 

  • Densem CG, Hutchinson IV, Yonan N et al (2002) Tumour necrosis factor alpha gene polymorphism: a predisposing factor to non-ischaemic myocardial dysfunction? Heart. 87: 153–155

    Article  PubMed  CAS  Google Scholar 

  • Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533.

    Google Scholar 

  • Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 273: 1450–6.

    Google Scholar 

  • Grainger DJ, Heathcote K, Chiano M et al (1999) Genetic control of the circulating concentration of transforming growth factor type betal. Hum Mol Genet. 8: 93–97

    Article  PubMed  CAS  Google Scholar 

  • Green SA, Cole G, Jacinto M et al (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 268 (31): 23116–23121

    PubMed  CAS  Google Scholar 

  • Hengstenberg C, Holmer SR, Mayer B et al (2000) Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 35 (3): 704–709

    Article  PubMed  CAS  Google Scholar 

  • Herrmann S, Schmidt-Petersen K, Pfeifer J et al (2001) A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 22: 1948–1953

    Article  PubMed  CAS  Google Scholar 

  • Hoffmeyer S, Burk O, von Richeter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473–3478

    Article  PubMed  CAS  Google Scholar 

  • Hoit BD, Suresh DP, Craft L et al (2000) Beta 2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 139: 537–542.

    PubMed  CAS  Google Scholar 

  • Holweg CT, Baan CC, Niesters HG et al (2001) TGF-betal gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant. 20: 979–984

    Article  PubMed  CAS  Google Scholar 

  • Ichihara S, Yamada Y, Yokota M (1998) Association of a G994−>T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation. 98: 1881–1885

    Article  PubMed  CAS  Google Scholar 

  • Isner IM (2002) Myocardial gene therapy. Nature 415: 234–9

    Article  PubMed  CAS  Google Scholar 

  • Jia H, Hingorani AD, Sharma Pet al (1999) Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension. 34: 8–14

    Article  PubMed  CAS  Google Scholar 

  • Kirshenbaum LA, de Moissac D (1997) The bd-2 gene product prevents programmed cell death of ventricular myocytes. Circulation. 96: 1580–1585

    Article  PubMed  CAS  Google Scholar 

  • Komajda M, Charron P, Tesson F (1999) Genetic aspects of heart failure. Eur J H Fail 1: 121–126

    Article  CAS  Google Scholar 

  • Kupari M, Hautanen A, Lankinen L et al (1998) Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation. 97: 569–575

    Article  PubMed  CAS  Google Scholar 

  • Kurland L, Melhus H, Karlsson J et al (2001) Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 19: 1783–1787

    Article  PubMed  CAS  Google Scholar 

  • Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323: 236–241

    Article  PubMed  CAS  Google Scholar 

  • Li RK, Li G, Mickle DA et al (1997) Overexpression of transforming growth factor-betal and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 96: 874–881

    Article  PubMed  CAS  Google Scholar 

  • Liggett SB, Wagoner LE, Craft LL et al (1998) The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102: 1534–1539

    Article  PubMed  CAS  Google Scholar 

  • Loh E, Rebbeck TR, Mahoney PD et al (1999) Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99: 1422–1425

    Article  PubMed  CAS  Google Scholar 

  • MacFadyen RJ, Lee AF, Morton JJ et al (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82: 57–61

    PubMed  CAS  Google Scholar 

  • Manunta P, Cusi D, Barlassina C et al (1998) Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 53: 1471–1478

    Article  PubMed  CAS  Google Scholar 

  • Mason DA, Moore JD, Green SA et al (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human betal-adrenergic receptor. J Biol Chem 274 (18): 12670–1264

    Article  PubMed  CAS  Google Scholar 

  • Matsui T, Li L, del Monte F et al (1999) Adenoviral gene transfer of activated phosphatidylinositol 3’-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373–2379

    Article  PubMed  CAS  Google Scholar 

  • MacGowan GA, McNamara DM. (2002) New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. Ir J Med Sci 171 (2): 99–104

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJ, Stewart S (2000) Epidemiology, aetiology and prognosis of heart failure. Heart 83: 596–602.

    Article  PubMed  CAS  Google Scholar 

  • McNamara DM, Holubkov R, Janosko K et al (2001) Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 103: 1644–1648

    Article  PubMed  CAS  Google Scholar 

  • MERIT-HF Investigators. (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001–7.

    Article  Google Scholar 

  • Miller JA, Thai K, Scholey JW (1999) Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 56: 2173–2180

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto MI, del Monte F, Schmidt U et al (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA. 97: 793–798

    Article  PubMed  CAS  Google Scholar 

  • Montgomery HE, Keeling PJ, Goldman JH et al (1995) Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2: 1627–1631

    Article  Google Scholar 

  • Morisaki T, Gross M, Morisaki H et al (1992) Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 89 (14): 6457–6461

    Article  PubMed  CAS  Google Scholar 

  • O’Shaughnessy KM, Fu B, Dickerson C et al (2000) The gain-of-function G389R variant of the betal-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 99: 233–238

    Article  Google Scholar 

  • O’Toole L, Stewart M, Padfield P et al (1998) Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 32: 988–994

    Article  PubMed  Google Scholar 

  • Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658

    Article  PubMed  CAS  Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 355: 1582–1587

    Article  PubMed  CAS  Google Scholar 

  • Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717

    Google Scholar 

  • Podlowski S, Wenzel K, Luther HP et al (2000) Betal-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 78: 87–93

    Article  PubMed  CAS  Google Scholar 

  • Port JD, Bristow MR (2001) Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 33: 887–905

    Article  PubMed  CAS  Google Scholar 

  • Raynolds MV, Bristow MR, Bush EW et al (1993) Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342: 1073–1075

    Article  PubMed  CAS  Google Scholar 

  • Rusnak JM, Kisabeth RM, Herbert DP et al (2001) Pharmacogenomics: a clinician’s prim- er on emerging technologies for improved patient care. Mayo Clin Proc 76: 299–309

    Article  PubMed  CAS  Google Scholar 

  • Sanderson JE, Young RP, Yu CM et al (1996) Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischaemic or idiopathic dilated cardiomyopathy in the Chinese. Am J Cardiol 77: 1008–1010

    Article  PubMed  CAS  Google Scholar 

  • Seidman JG, Seidman C (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104: 557–567

    Article  PubMed  CAS  Google Scholar 

  • Small KM, Wagoner LE, Levin AM et al (2002) Synergistic polymorphisms of betal-and alpha2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 347 (15): 1135–1142

    Article  PubMed  CAS  Google Scholar 

  • Stafforini DM, Satoh K, Atkinson DL et al (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97 (12): 2784–2791

    Article  PubMed  CAS  Google Scholar 

  • Tiago AD, Badenhorst D, Skudicky D et al (2002) An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 54 (3): 584–589

    Article  PubMed  CAS  Google Scholar 

  • Tiret L, Bonnardeaux A, Poirier O et al (1994) Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344: 910–913

    Article  PubMed  CAS  Google Scholar 

  • Tiret L, Mallet C, Poirier O et al (2000) Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy. The CARDIGENE study. J Am Coll Cardiol 35: 29–35

    Google Scholar 

  • Tiret L, Rigat B, Visvikis S et al. (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme ( ACE) gene controls plasma ACE levels. Am J H Gen 51: 197–205

    Google Scholar 

  • Todd GP, Chadwick IG, Higgins KS et al (1995) Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 39: 131–134

    Article  PubMed  CAS  Google Scholar 

  • Vancura V, Hubacek J, Malek I et al (1999) Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy? Am J Cardiol 83: 461–462

    Article  PubMed  CAS  Google Scholar 

  • Wagoner LE, Craft LL, Zengel P et al (2002) Polymorphisms of the beta(1)-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 144 (5): 840–846

    PubMed  CAS  Google Scholar 

  • Wagoner LE, Craft LL, Singh B et al (2000) Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 86: 834–40

    Article  PubMed  CAS  Google Scholar 

  • Wang XL, Liu SX, Wilcken DEI (1997) Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res. 34 (2): 404–410

    Article  PubMed  CAS  Google Scholar 

  • Weig HJ, Laugwitz KL, Moretti A et al (2000) Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 101: 1578–1585

    Article  PubMed  CAS  Google Scholar 

  • White HL, de Boer RA et al (2002) An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in patients with heart failure: A MERIT-HF substudy. EHJ Suppl 1 (1): 26.

    Google Scholar 

  • Wilson AG, Symons JA, McDowell TL et al (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94 (7): 3195–3199

    Article  PubMed  CAS  Google Scholar 

  • Zolk O, Quattek J, Sitzler G et al (1999) Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99 (16): 2118–2123

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow, G11 6NT, UK

    T. Stanton

  2. MRC Blood Pressure Unit, Division of Cardiovascular and Medical Sciences, Western Infirmary, University of Glasgow, Glasgow, Gl l 6NT, UK

    J. M. C. Connell

  3. Clinical Research Initiative in Heart Failure, Department of Medicine, University of Glasgow, West Medical Building, Glasgow, G12 8QQ, UK

    J. J. V. McMurray

Authors
  1. T. Stanton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. C. Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. J. V. McMurray
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Experimental Medicine & Toxicology Imperial College London, Hammersmith Campus, Du Cane Road, W12 0NN, London, UK

    Martin R. Wilkins (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stanton, T., Connell, J.M.C., McMurray, J.J.V. (2004). Genetic Determinants of Susceptibility, Prognosis and Treatment in Heart Failure. In: Wilkins, M.R. (eds) Cardiovascular Pharmacogenetics. Handbook of Experimental Pharmacology, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06214-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-06214-2_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-07291-8

  • Online ISBN: 978-3-662-06214-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation